Vnitr Lek 2009, 55(Suppl 1):94-96

Prothrombotic state in NAFLD and its consequences

A. Hvizdáková*, M. Vyskočil, Ľ. Kekeňák, E. Kováčová, H. Kratochvíľová, M. Boča
I. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednostka doc. MUDr. Soňa Kiňová, PhD.

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in population. NAFLD is one part of metabolic syndrome (MS). The liver plays the role in haemostasis by the synthesis of coagulant, anticoagulant factors and haemostasis regulation. It seems recently, that there are prothrombic changes in haemostasis in patients with MS and NAFLD. They are caused by endothelial dysfunction, hypofibrinolysis and hypercoagulant state. Prothrombotic state in patients with NAFLD can by means of the insulin resistance increase cardiovascular risk as well as the risk of thromboembolism. The formation of microthrombi in hepatic vessels can participate also in progression of simple steatosis to steatofibrosis and liver cirrhosis.

Keywords: NAFLD; endothelial dysfunction; prothrombotic state; cardiovascular risk

Received: March 31, 2009; Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hvizdáková A, Vyskočil M, Kekeňák Ľ, Kováčová E, Kratochvíľová H, Boča M. Prothrombotic state in NAFLD and its consequences. Vnitr Lek. 2009;55(Supplementum 1):94-96.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hvizdáková A, Boča M, Brnka R. Nealkoholová tuková choroba pečene (NAFLD) - choroba, ktorá sa v praxi často podceňuje. Inter Med 2008; 4: 227-232.
    2. Brodanová M, Kordač V. Klinická hepatologie. Praha: Grada Avicenum 1993: 40-43.
    3. Esper RJ, Nordaby RA, Vilariño JO et al. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4. Go to original source... Go to PubMed...
    4. Takase B, Matsushima Y, Uehata A et al. Endothelial dysfunction, carotid artery plaque burden, and conventional exercise-induced myocardial ischemia as predictors of coronary artery disease prognosis. Cardiovasc Ultrasound 2008; 6: 61. Go to original source... Go to PubMed...
    5. Brea A, Mosquera D, Martín E et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005; 25: 1045-1050. Go to original source... Go to PubMed...
    6. Villanova N, Moscatiello S, Ramilli S et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-480. Go to original source... Go to PubMed...
    7. Yildirim A, Soylu Ö, Aydin A et al. The relationship between endothelial dysfunction and serum aminotransferase levels in nonalcoholic fatty liver disease. Türk Kardiyol Dern Arş 2007; 35: 354-359.
    8. Targher G. Non-alcoholic fatty liver disease as a determinant of cardiovascular disease. Atherosclerosis 2007; 190: 18-19. Go to original source... Go to PubMed...
    9. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-1883. Go to original source... Go to PubMed...
    10. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357-1364. Go to original source... Go to PubMed...
    11. Marchesini G, Bugianesi E, Forlani G et al. Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res Clin Pract 2004; 63: 143-151. Go to original source... Go to PubMed...
    12. Targher G, Bertolini L, Scala L et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005; 22: 1354-1358. Go to original source... Go to PubMed...
    13. Derosa G, Gaddi AV, Piccinni MN et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy 2005; 25: 637-645. Go to original source... Go to PubMed...
    14. Bahia L, Aguiar LG, Villela N et al. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics 2006; 61: 433-440. Go to original source... Go to PubMed...
    15. Durina J, Remkova A. Prothrombotic state in metabolic syndrome. Bratisl Lek Listy 2007; 6: 279-280.
    16. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518. Go to original source... Go to PubMed...
    17. Vischer UM. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186-1193. Go to original source... Go to PubMed...
    18. Assy N, Bekirov I, Mejritsky Y et al. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005; 11: 5834-5839. Go to original source... Go to PubMed...
    19. Kurihara T, Deguchi S, Kato J et al. Impaired blood rheology by remnant-like lipoprotein particles: Studies in patients with fatty liver disease. Clin Hemorheol Microcirc 2001; 24: 217-225.
    20. Northup PG, Sundaram V, Fallon MB et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2007; 6: 2-9. Go to original source... Go to PubMed...
    21. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004; 24: 99-106. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.